The Apex Times
Above the Noise
Business Wire
BusinessCaterpillar shares give back gains after a sharp early-October tumbleThe Apex TimesBusinessKFC’s U.S. Coca-Cola switch outlines a fresh pull for The Coca-Cola Company as PepsiCo loses a key refreshment tapThe Apex TimesBusinessTesla’s Flying Roadster Revives SpaceX Comparisons, but Investors Say It’s Not a Product Roadmap ItemThe Apex TimesBusinessBattery X Metals draws attention at Tesla-hosted venue for X Takeover 2026 electric-vehicle and emerging-tech eventThe Apex TimesBusinessFounder of $13k MRR lifting app says Meta beats TikTok for early app marketingThe Apex TimesBusinessBristol-Myers Squibb screens cheaper than Johnson & Johnson, but leverage and patent overhang drive the debateThe Apex TimesBusinessStarlink Mobile raises a question for Apple: could US carrier subsidies come under pressure?The Apex TimesBusinessStarbucks shares trade at a premium as investors bet foot traffic can hold upThe Apex TimesBusinessStocktwits roundup points to a new chapter for Tesla’s Roadster, while Rivian and Lucid press their own timelinesThe Apex TimesBusinessApple Shareholders’ Recent Positioning Reflect a Year of Product, Leadership, and AI-Related Legal NoiseThe Apex TimesBusinessWalmart’s valuation looks premium, but peers’ performance metrics tell a mixed storyThe Apex TimesBusinessUPS Worker’s Meal-Prep Side Business Scaled to “Seven Figures” After He Bootstrapped ItThe Apex TimesBusinessCaterpillar shares give back gains after a sharp early-October tumbleThe Apex TimesBusinessKFC’s U.S. Coca-Cola switch outlines a fresh pull for The Coca-Cola Company as PepsiCo loses a key refreshment tapThe Apex TimesBusinessTesla’s Flying Roadster Revives SpaceX Comparisons, but Investors Say It’s Not a Product Roadmap ItemThe Apex TimesBusinessBattery X Metals draws attention at Tesla-hosted venue for X Takeover 2026 electric-vehicle and emerging-tech eventThe Apex TimesBusinessFounder of $13k MRR lifting app says Meta beats TikTok for early app marketingThe Apex TimesBusinessBristol-Myers Squibb screens cheaper than Johnson & Johnson, but leverage and patent overhang drive the debateThe Apex TimesBusinessStarlink Mobile raises a question for Apple: could US carrier subsidies come under pressure?The Apex TimesBusinessStarbucks shares trade at a premium as investors bet foot traffic can hold upThe Apex TimesBusinessStocktwits roundup points to a new chapter for Tesla’s Roadster, while Rivian and Lucid press their own timelinesThe Apex TimesBusinessApple Shareholders’ Recent Positioning Reflect a Year of Product, Leadership, and AI-Related Legal NoiseThe Apex TimesBusinessWalmart’s valuation looks premium, but peers’ performance metrics tell a mixed storyThe Apex TimesBusinessUPS Worker’s Meal-Prep Side Business Scaled to “Seven Figures” After He Bootstrapped ItThe Apex TimesBusinessCaterpillar shares give back gains after a sharp early-October tumbleThe Apex TimesBusinessKFC’s U.S. Coca-Cola switch outlines a fresh pull for The Coca-Cola Company as PepsiCo loses a key refreshment tapThe Apex TimesBusinessTesla’s Flying Roadster Revives SpaceX Comparisons, but Investors Say It’s Not a Product Roadmap ItemThe Apex TimesBusinessBattery X Metals draws attention at Tesla-hosted venue for X Takeover 2026 electric-vehicle and emerging-tech eventThe Apex TimesBusinessFounder of $13k MRR lifting app says Meta beats TikTok for early app marketingThe Apex TimesBusinessBristol-Myers Squibb screens cheaper than Johnson & Johnson, but leverage and patent overhang drive the debateThe Apex TimesBusinessStarlink Mobile raises a question for Apple: could US carrier subsidies come under pressure?The Apex TimesBusinessStarbucks shares trade at a premium as investors bet foot traffic can hold upThe Apex TimesBusinessStocktwits roundup points to a new chapter for Tesla’s Roadster, while Rivian and Lucid press their own timelinesThe Apex TimesBusinessApple Shareholders’ Recent Positioning Reflect a Year of Product, Leadership, and AI-Related Legal NoiseThe Apex TimesBusinessWalmart’s valuation looks premium, but peers’ performance metrics tell a mixed storyThe Apex TimesBusinessUPS Worker’s Meal-Prep Side Business Scaled to “Seven Figures” After He Bootstrapped ItThe Apex TimesBusinessCaterpillar shares give back gains after a sharp early-October tumbleThe Apex TimesBusinessKFC’s U.S. Coca-Cola switch outlines a fresh pull for The Coca-Cola Company as PepsiCo loses a key refreshment tapThe Apex TimesBusinessTesla’s Flying Roadster Revives SpaceX Comparisons, but Investors Say It’s Not a Product Roadmap ItemThe Apex TimesBusinessBattery X Metals draws attention at Tesla-hosted venue for X Takeover 2026 electric-vehicle and emerging-tech eventThe Apex TimesBusinessFounder of $13k MRR lifting app says Meta beats TikTok for early app marketingThe Apex TimesBusinessBristol-Myers Squibb screens cheaper than Johnson & Johnson, but leverage and patent overhang drive the debateThe Apex TimesBusinessStarlink Mobile raises a question for Apple: could US carrier subsidies come under pressure?The Apex TimesBusinessStarbucks shares trade at a premium as investors bet foot traffic can hold upThe Apex TimesBusinessStocktwits roundup points to a new chapter for Tesla’s Roadster, while Rivian and Lucid press their own timelinesThe Apex TimesBusinessApple Shareholders’ Recent Positioning Reflect a Year of Product, Leadership, and AI-Related Legal NoiseThe Apex TimesBusinessWalmart’s valuation looks premium, but peers’ performance metrics tell a mixed storyThe Apex TimesBusinessUPS Worker’s Meal-Prep Side Business Scaled to “Seven Figures” After He Bootstrapped ItThe Apex Times
Back to front
Jim Cramer cited Johnson & Johnson’s balance sheet as a reason investors should look past worries
The Apex Times

THE APEX TIMES

Business/The Apex Times/Aug 28, 2:03 PM EDT

Jim Cramer cited Johnson & Johnson’s balance sheet as a reason investors should look past worries

A recent Yahoo Finance report highlighted CNBC host Jim Cramer’s recurring bullish view of Johnson & Johnson, pointing to what he framed as a stronger balance sheet than the government’s.

By The Apex Times Newsroom2 min readAI-assisted Apex article

Johnson & Johnson’s stock has again surfaced in a high-profile endorsement from CNBC host Jim Cramer, according to a Yahoo Finance report published Aug. 28, 2026. The piece said Cramer has repeatedly praised the health care company during the year and that one of his central reasons is the balance sheet strength he attributes to Johnson & Johnson.

The report’s focus was not on a specific product launch, earnings beat, or contract award. Instead, it framed Johnson & Johnson as a business with financial staying power, pointing to balance-sheet resilience as a counterweight to broader market uncertainty.

Cramer’s comment, as described by Yahoo Finance, leaned on a comparison in which he characterized Johnson & Johnson’s balance sheet as “better” than what he implied about the government. The report did not provide additional context around what government measure Cramer had in mind, nor did it lay out any figures or accounting detail in the excerpt available for review.

The endorsement fits a pattern in which large, diversified health care companies are often treated by Wall Street and broadcast commentators as steadier holdings than smaller, more single-asset firms. Johnson & Johnson’s scale and long operating history can matter in discussions of credit risk, cash generation, and the ability to fund development pipelines through market cycles.

Still, the Yahoo Finance post did not disclose any new company-specific metrics in the material available for editorial review. It also did not specify whether Cramer’s remarks were tied to a particular filing, credit rating update, or a recent investor presentation, which limits how far readers can go in validating the balance-sheet claim.

For investors and analysts, the immediate takeaway is that the conversation around Johnson & Johnson in this instance was driven by financial durability rather than a discrete catalyst. What happens next, notably in the company’s next quarterly reporting cycle or any debt and liquidity disclosures, will determine whether that durability view is reinforced by updated numbers.

Why It Matters

  • High-profile commentary can influence short-term sentiment, particularly for large-cap health care names that investors often view as lower-volatility relative to smaller companies.
  • Balance-sheet strength is a key input to how investors think about liquidity risk and a company’s ability to continue funding operations and pipeline activities through downturns.
  • Because the comparison to “the government” was not quantified in the available text, readers may need to look to Johnson & Johnson’s next filings to understand what financial measures are being implied.
  • If the market interprets Cramer’s remarks as indicating resilience without a near-term catalyst, it could support sustained interest in the stock even when newsflow is light.

Sources

Key Facts

  • Yahoo Finance reported on Aug. 28, 2026 that Jim Cramer has repeatedly praised Johnson & Johnson during the year.
  • The report characterizes Cramer’s view of Johnson & Johnson as tied to balance-sheet strength.
  • The Yahoo Finance piece includes a comparison in which Cramer framed Johnson & Johnson’s balance sheet as stronger than what he implied about the government.
  • The available report excerpt did not include specific Johnson & Johnson balance-sheet figures or the specific government reference behind the comparison.
  • The company’s ticker is Johnson & Johnson (NYSE:JNJ), as referenced by the Yahoo Finance headline.

Healthcare Related

Jim Cramer cited Johnson & Johnson’s balance sheet as a reason investors should look past worries | The Apex Times